stockrow
Friday 6 November 2026
Export RKDA’s income statement to Excel — free account
Arcadia Biosciences, Inc.
RKDA Consumer Defensive Packaged Foods
Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024.
- Revenue
- −0.82%
- EPS
- +35.9%
- Free cash flow
- +82.1%
Quarter to June 2026, against a year earlier
0.16
0.01
−5.88%
Follow RKDA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 3 | 4 | 1 | 1 | 8 | 7 | 7 | 4 | 5 | 5 | 5 | +4.8% | 8 | — | — | +58.5% | |
| Gross margin, % | 71.93 | 92.97 | 54.85 | 24.29 | 35.29 | (28.44) | 17.75 | 51.19 | 41.27 | 36.23 | 34.60 | (35.7) pt | ||||||
| EBT | (20) | (16) | (13) | (29) | (6) | (16) | (11) | (5) | (4) | (2) | (11) | (21.1%) | ||||||
| EBT margin, % | (614.77) | (389.49) | (920.08) | (2,469.72) | (76.55) | (237.94) | (145.78) | (119.47) | (85.41) | (47.98) | (234.37) | +566.8 pt | ||||||
| Net income | (20) | (16) | (13) | (29) | (6) | (16) | (16) | (14) | (7) | (2) | (11) | (21.0%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 57.44 | 74.69 | 15.54 | 7.35 | 32.27 | 12.74 | 12.38 | 3.60 | 3.70 | 3.55 | 1.59 | (26.6%) | |||||
| Earnings | (352.00) | (291.20) | (143.20) | (181.20) | (18.80) | (27.60) | (25.65) | (11.30) | (5.17) | (1.71) | (4.55) | (44.7%) | ||||||
| Cash flow | (307.30) | (259.09) | (144.70) | (108.10) | (121.36) | (48.62) | (23.33) | (12.36) | (7.06) | (3.46) | (0.85) | (39.2%) | ||||||
| Capex | (4.16) | (1.39) | (2.55) | (9.18) | (9.35) | (1.86) | 1.42 | 0.09 | 3.17 | 0.55 | 0.00 | n/m | ||||||
| Free cash flow | (311.46) | (260.48) | (147.25) | (117.28) | (130.70) | (50.48) | (21.92) | (12.27) | (3.90) | (2.92) | (0.85) | (40.5%) | ||||||
| Book value | 399.96 | 148.55 | 136.04 | 52.33 | 114.67 | 58.64 | 34.89 | 10.27 | 4.57 | 3.03 | 0.21 | (41.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | +42.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 12.53 | 2.89 | 8.16 | 29.83 | 3.14 | 3.26 | 0.90 | 0.81 | 1.60 | 0.56 | 0.11 | 6.4 | ||||||
| P/B | 1.80 | 1.45 | 0.93 | 4.19 | 0.88 | 0.71 | 0.32 | 0.28 | 1.30 | 0.65 | 0.80 | 1.3 | ||||||
| EV/Sales | 4.56 | 4.88 | 7.64 | 8.28 | 0.35 | (0.95) | (1.86) | (1.78) | 0.78 | (0.36) | (0.75) | 2.2 | ||||||
| EV/FCF | (0.84) | (1.40) | (0.81) | (0.52) | (0.09) | 0.24 | 1.05 | 0.52 | (0.42) | (1.61) | (1.08) | (0.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (17) | (14) | (14) | (17) | (30) | (26) | (14) | (15) | (10) | (5) | (3) | (13.3%) | |||||
| Capex | 0 | 0 | 0 | (1) | (2) | (1) | 1 | 0 | 4 | 1 | 6 | n/m | ||||||
| Free cash flow | (17) | (14) | (14) | (19) | (33) | (27) | (13) | (15) | (5) | (4) | (3) | (15.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 49 | 12 | 20 | 23 | 25 | 30 | 21 | 11 | 7 | 4 | 4 | (23.7%) | |||||
| Net debt | (25) | (13) | (22) | (25) | (22) | (29) | (21) | (12) | (4) | (5) | (4) | (17.4%) | ||||||
| Shareholders’ equity | 22 | 8 | 13 | 8 | 29 | 31 | 21 | 13 | 6 | 4 | 1 | (17.0%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (30.00) | (42.95) | (66.41) | (101.79) | (11.65) | (32.13) | (42.22) | (57.50) | (42.37) | (23.32) | (162.72) | +6.7 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (130.26) | (884.26) | (3,419.68) | (359.45) | (115.09) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (62.87) | (104.00) | (129.48) | (272.50) | (25.25) | (49.07) | (59.03) | (83.21) | (74.37) | (45.14) | (430.93) | +17.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 57 | 42 | 24 | 61 | 11 | 11 | 30 | 21 | 9 | 8 | — | (19.6%) | |||||
| Revenue/emp, $m | 0.06 | 0.10 | 0.06 | 0.02 | 0.73 | 0.62 | 0.25 | 0.21 | 0.56 | 0.61 | — | +30.3% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Arcadia Biosciences, Inc. vs peers in Packaged Foods (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NCRA Nocera, Inc. | $3.4M | — (loss-making) | — | −28.52% (below 0%: shrinking) | n/m | −194.28% (below 0%: shrinking) | 0.84% | (54.90%) | Compare |
| PAVS Paranovus Entertainment Technology Ltd. | $2.4M | — (loss-making) | — (loss-making) | −8.96% (below 0%: shrinking) | −582.47% (below 0%: shrinking) | +88.21% (above 0%: growing) | 5.59% | 0.00% | Compare |
| ORISF Oriental Rise Holdings Limited | $2.3M | — | — | — | — | −105.36% (below 0%: shrinking) | — | — | Compare |
| MEHA Functional Brands Inc. | $1.9M | — (loss-making) | — | +2.07% (above 0%: growing) | n/m | −209.98% (below 0%: shrinking) | 59.89% | (70.59%) | Compare |
| CYAN Cyanotech Corporation | $1.7M | — (loss-making) | 2.4× | +11.12% (above 0%: growing) | n/m | +204.00% (above 0%: growing) | 42.38% | 7.00% | Compare |
| ATPC Agape ATP Corporation | $1.3M | — (loss-making) | — | −93.38% (below 0%: shrinking) | n/m | +77.69% (above 0%: growing) | 86.13% | (4,021.90%) | Compare |
| BSFCD Blue Star Foods Corp. | $960.0K | 0.0× | 2.3× | −54.59% (below 0%: shrinking) | n/m | −123.09% (below 0%: shrinking) | 55.80% | (29.04%) | Compare |
| STKH Steakholder Foods Ltd. Sponsored ADR | $440.0K | — (loss-making) | — | — | n/m | +35.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| RKDA Arcadia Biosciences, Inc. | $400.0K | — (loss-making) | — (loss-making) | −0.82% (below 0%: shrinking) | n/m | +82.11% (above 0%: growing) | 43.73% | (34.37%) | |
| Median of peers | $1.8M | — | — | −18.74% | — | −34.87% | 42.38% | (29.04%) |
Pay and ownership Proxy statement filed 10 August 2026
Ownership
Directors and executive officers, together
4.50%
Sabby Volatility Warrant Master Fund, Ltd.
9.90%
Armistice Capital Master Fund Ltd.
9.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement